Joseph A Buechler

US Patent:

8221995, Jul 17, 2012

Filed:

Jun 27, 2008

Appl. No.:

12/663841

Inventors:

Seok-Won Lee - San Diego CA, US
Kelline M. Rodems - Oceanside CA, US
David W. Oelschlager - San Diego CA, US
Uday Kumar Veeramallu - San Diego CA, US
Joseph A. Buechler - Carlsbad CA, US
Paul H. McPherson - Encinitas CA, US

International Classification:

G01N 33/00

US Classification:

435 794

Abstract:

The present invention relates to methods and compositions for diagnosing SIRS, sepsis, severe sepsis, septic shock, or MODS in a subject, or assigning a prognostic risk for one or more clinical outcomes for a subject suffering from SIRS, sepsis, severe sepsis, septic shock, or MODS, the method comprising performing an immunoassay for CCL23 splice variant.

US Patent:

20060051825, Mar 9, 2006

Filed:

Sep 7, 2005

Appl. No.:

11/222494

Inventors:

Kenneth Buechler - Rancho Santa Fe CA, US
Joseph Buechler - Carlsbad CA, US

International Classification:

G01N 33/53
G01N 33/537
G01N 33/543

US Classification:

435007930

Abstract:

The present invention describes compositions and methods designed to determine the presence or amount of BNP or fragments thereof in a sample. In particular, the invention provides materials that may be configured to bind canine BNP in a sandwich assay format. The present invention provides, inter alia, assays designed to rapidly and accurately measure BNP-related species in non-human animals.

US Patent:

20090004755, Jan 1, 2009

Filed:

Jun 28, 2007

Appl. No.:

11/770608

Inventors:

Seok-Won Lee - San Diego CA, US
Kelline M. Rodems - Oceanside CA, US
David W. Oelschlager - San Diego CA, US
Uday Kumar Veeramallu - San Diego CA, US
Joseph A. Buechler - Carlsbad CA, US
Paul H. McPherson - Encinitas CA, US

International Classification:

G01N 33/566

US Classification:

436501

Abstract:

The present invention relates to methods and compositions for diagnosing SIRS, sepsis, severe sepsis, septic shock, or MODS in a subject, or assigning a prognostic risk for one or more clinical outcomes for a subject suffering from SIRS, sepsis, severe sepsis, septic shock, or MODS, the method comprising performing an immunoassay for CCL23 splice variant.

US Patent:

20090061467, Mar 5, 2009

Filed:

Jul 10, 2008

Appl. No.:

12/171245

Inventors:

Kenneth F. Buechler - Rancho Santa Fe CA, US
Joseph Buechler - Carlsbad CA, US

Assignee:

BIOSITE INCORPORATED - San Diego CA

International Classification:

G01N 33/53
C07K 16/00

US Classification:

435 794, 5303873

Abstract:

The present invention describes compositions and methods designed to determine the presence or amount of BNP or fragments thereof in a sample. In particular, the invention provides materials that may be configured to bind canine BNP in a sandwich assay format. The present invention provides, inter alia, assays designed to rapidly and accurately measure BNP-related species in non-human animals.

US Patent:

20100272635, Oct 28, 2010

Filed:

Jun 13, 2008

Appl. No.:

12/663699

Inventors:

Kelline M. Rodems - Oceanside CA, US
David W. Oelschlager - San Diego CA, US
Uday Kumar Veeramallu - San Diego CA, US
Joseph Buechler - Carlsbad CA, US

International Classification:

A61K 51/00
A61K 49/00
A61K 49/06
A61K 49/22
G01N 33/53

US Classification:

424 111, 424 91, 424 93, 424 95, 435 794

Abstract:

Methods and compositions for diagnosis, prognosis and monitoring of ovarian cancer and lung cancer are provided. Assays that detect NHERF-I (or one or more markers related thereto) and NHERF-I-containing complexes are used to assign a diagnosis to a subject being assessed for the presence of ovarian or lung cancer; assign a prognostic risk to a subject suffering from ovarian or lung cancer; or monitor the course of ovarian or lung cancer treatment in a subject.

US Patent:

7655428, Feb 2, 2010

Filed:

Dec 21, 2006

Appl. No.:

11/614836

Inventors:

Gunars E. Valkirs - Escondido CA, US
Joseph A. Buechler - Carlsbad CA, US
Seok-Won Lee - San Diego CA, US
Uday Kumar Veeramallu - San Diego CA, US

Assignee:

Biosite, Inc. - Waltham MA

International Classification:

G01N 21/00
G01N 21/64
G01N 21/75
G01N 21/76
G01N 25/18
G01N 33/00
A61K 39/00
A61K 39/395
A61K 39/44

US Classification:

435 793, 435 4, 435 71, 435 792, 436149, 436164, 436172, 422 681, 422 8201, 422 8205, 422 8206, 422 8207, 422 8208, 4241301, 4241331, 4241411

Abstract:

The present invention relates to methods and compositions for measuring latent protein C in test samples, particularly patient samples. The methods and compositions described are sensitive for latent protein C, relative to activated protein C.

US Patent:

20140315734, Oct 23, 2014

Filed:

Jul 3, 2012

Appl. No.:

14/130209

Inventors:

William D. Arnold - San Diego CA, US
Christelle Jost - San Diego CA, US
Brian Noland - Temecula CA, US
Jonathan Gary - San Diego CA, US
Joseph Buechler - Carlsbad CA, US
Vance Wong - Cardiff CA, US
Scott Harold Rongey - San Diego CA, US
Uday Kumar Veeramallu - San Diego CA, US
Kelline Marie Rodems - Oceanside CA, US

Assignee:

ALERE SAN DIEGO INC. - San Diego CA

International Classification:

G01N 33/68

US Classification:

506 9, 435 792, 435 612, 4352872

Abstract:

The invention encompasses diagnosis and prognosis in the context of heart or renal failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The invention also relates to methods of assigning an increased likelihood that a subject having AKI is susceptible to AKI progression. The invention relates in part to assigning a diagnosis of heart and/or renal failure, and/or an outcome risk (e.g., worsening cardiac and/or renal function or a mortality risk) to a subject based, at least in part, on the result(s) obtained from an assay that detects WAP four-disulfide core domain protein 2 performed on a body fluid sample obtained from a subject.

US Patent:

20140147867, May 29, 2014

Filed:

Nov 25, 2011

Appl. No.:

13/990393

Inventors:

William D. Arnold - San Diego CA, US
Christelle Jost - San Diego CA, US
Brian Noland - Temecula CA, US
Jonathan Gary - San Diego CA, US
Joseph Buechler - Carlsbad CA, US
Vance Wong - Cardiff CA, US
Scott Harold Rongey - San Diego CA, US
Uday Kumar Veeramallu - San Diego CA, US
Kelline Marie Rodems - Oceanside CA, US

Assignee:

ALERE SAN DIEGO, INC. - San Diego CA

International Classification:

G01N 33/68

US Classification:

435 794, 435 792

Abstract:

The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.